Point prevalence of specific fears and phobias was determined in 704 respondents of 1000
randomly selected adults aged 18–70 yr. A phobia for lightning, enclosed spaces, darkness, …

Objective: Lithium, a first-line drug for the treatment of bipolar depression, has recently been
shown to regulate glycogen synthase kinase-3 (GSK-3), a kinase that is involved in the …

Preclinical and clinical studies gave evidence that lithium could be useful in the treatment of
Alzheimer's disease (AD). In experimental investigations, lithium induces brain-derived …

Biomarker levels in cerebrospinal fluid (CSF) may serve as surrogate markers for treatment
efficacy in clinical trials of disease-modifying drugs against Alzheimer's disease (AD). A …

Background Fear conditioning is a traditional model for the acquisition of fears and phobias.
Studies of the genetic architecture of fear conditioning may inform gene-finding strategies …

Background: This is the first meta-analysis of randomized placebo-controlled trials testing
lithium as a treatment for patients with Alzheimer’s disease (AD) and individuals with mild …

Biological markers for acquisition and extinction of fear conditioning were studied in 40
individuals selected for displaying either good or poor acquisiton of fear conditioning, as …

Microglia manage immunosurveillance and mediate inflammation, both suggested to be
important in Alzheimer's disease (AD). The aim of this study was to investigate if microglial …

Fears and phobias are relatively common in childhood. Both environmental and genetic
theories have tried to explain the etiology behind these conditions. However, data supporting …

Background Major Depressive Disorder (MDD) is prevalent, often chronic, and requires
ongoing monitoring of symptoms to track response to treatment and identify early indicators of …